[1] HargAdon KM,Johnson CE,Williams CJ. Immune checkpoint blo-ckade therapy for cancer:an overview of FDA-approved immune checkpoint inhibitors[J]. Int Immunopharmacol,2018,62:29-39. [2] 吴绮楠,童南伟. 《肿瘤相关性高血糖管理指南(2021年版)》解读[J]. 中国癌症杂志,2021,31(12):1153-1161. Wu QN,Tong NW.Interpretation of guidelines for the management of tumor-associated hyperglycemia(2021 edition)[J]. China Oncol,2021,31(12):1153-1161. [3] 张瑞,刘柳,蔡晓凌,等. 免疫检查点抑制剂治疗后发生1型糖尿病二例报道并文献综述[J]. 中国糖尿病杂志,2020,28(1):62-70. Zhang R,Liu L,Cai XL,et al.Two case reports of immune checkpoint inhibitors induced type 1 diabetes and literature review[J]. Chin J Diabetes,2020,28(1):62-70. [4] Imagawa A,Hanafusa T,Awata T,et al.Report of the Committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus:new diagnostic criteria of fulminant type 1 diabetes mellitus(2012)[J]. J Diabetes Investig,2012,3(6):536-539. [5] 陈优飞. 免疫检查点抑制剂致暴发性1型糖尿病合并酮症酸中毒三例[J]. 实用肿瘤杂志,2021,36(5):458-461. Chen YF.Three cases of fulminant type 1 diabetes mellitus with ketoacidosis caused by immune checkpoint inhibitors[J]. J Pract Oncol,2021,36(5):458-461. [6] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志,2021,13(4):315-409. Diabetes Branch of Chinese Medical Association. Guideline for the prevention and treatment of type 2 diabetes mellitus in China(2020 edition)[J]. Chin J Diabetes Mellitus,2021,13(4):315-409. [7] 张星,高玲玲,郭晓迪,等. 11例糖尿病酮症酸中毒昏迷患者合并重症急性胰腺炎的护理[J]. 中华护理杂志,2020,55(11):1701-1705. Zhang X,Gao LL,Guo XD,et al.Nursing care of 11 patients with severe acute pancreatitis and diabetic coma caused by diabetic ketoacidosis[J]. Chin J Nurs,2020,55(11):1701-1705. [8] 姜林,黄薇. 免疫检查点抑制剂应用后发生糖尿病一例报道[J]. 中华糖尿病杂志,2021(12):1174-1176. Jiang L,Huang W.A case of diabetes mellitus after the application of immune checkpoint inhibitors was reported[J]. Chin J Diabetes Mullitus,2021(12):1174-1176. [9] Yim C,Mansell K,Hussein N,et al.Current cancer therapies and their influence on glucose control[J]. World J Diabetes,2021,12(7):1010-1025. [10] ARIMA H,Iwama S,Inaba H,et al.Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors:clinical guidelines of the Japan Endocrine Society[J]. Endocr J,2019,66(7):581-586. [11] 施云,沈敏,顾愹,等. 免疫检查点抑制剂相关1型糖尿病[J]. 中华糖尿病杂志,2020,12(12):945-948. Shi Y,Shen M,Gu Y,et al.Immune checkpoint inhibitor-induced type 1 diabetes mellitus[J]. Chin J Diabetes Mellit,2020, 12(12):945-948. [12] 任尧尧,张琳琳,王瑜,等. 免疫检查点抑制剂相关糖尿病2例报道及文献回顾[J]. 中国肺癌杂志,2022,25(1):61-65. Ren YY,Zhang LL,Wang Y,et al.Immune checkpoint inhibitors related diabetes mellitus:a report of 2 cases and literature review[J]. Chin J Lung Cancer,2022,25(1):61-65. |